New Delhi, 21 May 2025: In a significant advancement for global health and disease prevention, Bharat Biotech has announced that its oral cholera vaccine candidate, Hillchol, has successfully cleared Phase 3 clinical trials. This marks a major step toward introducing a safer, more accessible, and efficient solution to combating cholera, a deadly waterborne disease that continues to affect millions worldwide, particularly in developing regions.
What is Hillchol?
Hillchol is an oral cholera vaccine developed by Hyderabad-based Bharat Biotech, a company globally recognised for its contributions to vaccine innovation, including the COVID-19 vaccine Covaxin. Unlike injectable cholera vaccines, Hillchol is administered orally, making it easier to distribute and administer, especially in remote or resource-poor areas. The vaccine is designed to provide protection against Vibrio cholerae — the bacterium that causes cholera, an acute diarrheal illness that can lead to death if untreated.
Phase 3 Trial Results
The Phase 3 trials of Hillchol were conducted on a large cohort across multiple sites in India. According to the company, the vaccine demonstrated strong safety and immunogenicity profiles, meeting the primary endpoints set for the study. It was well tolerated, with no significant adverse effects reported, and elicited a robust immune response in a large percentage of participants.
In a statement, Bharat Biotech noted, “The successful completion of Phase 3 trials marks a key milestone in our journey to provide an effective oral cholera vaccine. Hillchol’s performance reinforces our commitment to developing vaccines that are accessible, affordable, and easy to administer.”
The trial also confirmed that Hillchol induces a protective immune response against cholera in all age groups, including children, who are particularly vulnerable to the disease.
Why an Oral Cholera Vaccine is a Game Changer
Cholera continues to pose a serious public health threat in several parts of Asia, Africa, and Latin America, especially in areas with poor sanitation and limited access to clean drinking water. According to the World Health Organization (WHO), there are between 1.3 to 4 million cholera cases and up to 143,000 deaths worldwide every year.
Traditional cholera vaccines, although effective, often require cold chain logistics, multiple doses, and trained healthcare personnel for administration — factors that limit their usage in low-resource settings. In contrast, Hillchol’s oral formulation provides an easy-to-administer, needle-free option that could revolutionise how cholera is prevented in at-risk populations.
Regulatory Approval and Next Steps
With Phase 3 trials now complete, Bharat Biotech is expected to submit the data to India’s Drugs Controller General of India (DCGI) for final regulatory approval. If granted, Hillchol could become a key tool in India’s and global public health efforts to prevent cholera outbreaks, particularly in regions where the disease is endemic.
In addition to the Indian market, Bharat Biotech also aims to seek prequalification from the World Health Organization, which would allow global health agencies such as UNICEF and GAVI to procure the vaccine for large-scale immunisation campaigns in developing countries.
Bharat Biotech’s Growing Vaccine Portfolio
Hillchol adds to Bharat Biotech’s growing portfolio of over 16 vaccines, many of which are WHO-prequalified and distributed globally. The company has consistently been at the forefront of tackling emerging public health challenges, and Hillchol is yet another testament to its innovation-driven approach.
The clearance of Hillchol’s Phase 3 trials brings hope for the global fight against cholera. With its ease of use, safety, and effectiveness, the oral vaccine stands poised to transform how cholera prevention is approached, especially in vulnerable communities. As the world continues to battle waterborne diseases worsened by climate change and poor sanitation, vaccines like Hillchol could play a pivotal role in reducing mortality and improving global health equity.
Leave a comment